The company is finalizing production supply agreements with Bangladeshi pharmaceutical partners to produce Ivectosol 1% for use and distribution throughout the country
() (OTCQB:MVMDF) has said it is starting husbandry animal trials in Bangladesh for the company’s injectable solubilized Ivermectin technology, Ivectosol 1%.
Bangladesh’s foreign minister HE Dr AK Abdul Momen welcomed the Toronto-based company to the country in a statement Tuesday.
“We are very excited to be welcoming Mountain Valley MD to The People’s Republic of Bangladesh and are proud that they have selected our country for important research projects and as a key production hub for its solubilized Ivectosol 1% product,” Momen said.
Mountain Valley MD will be working under the supervision of Bangladesh’s Ministry of Fisheries & Livestock on the trials.
Ivectosol 1%, a fully solubilized form of the anti-parasitic drug Ivermectin, will be tested in cattle, goat and poultry under the supervision of the Bangladesh government’s approved and authorized laboratories and research institutes, Mountain Valley told investors.
The tests will be conducted by way of intra-muscular needleless injection of Ivectosol 1% in bid to demonstrate superior pharmacokinetics in terms of CMAX (peak serum concentration that a drug achieves) and AUC (area under the curve) with advanced drug withdrawal time control, versus current commercially available forms.
The company is working with local partner R&G Group of Bangladesh to quickly advance research, development and manufacturing capabilities inside the country, it told investors.
Trials are set to begin in early April and will last around 30 days, the company said.
DEEP DIVE: Mountain Valley MD looking to eradicate needles with its patented Quicksome oral drug delivery technology
Mountain Valley MD is finalizing production supply agreements with Bangladeshi pharmaceutical partners to produce Ivectosol 1% for use and distribution throughout the country, and to use Bangladesh as a supply hub for wider global distribution.
“We’ve been extremely impressed by the speed and pace with which the Government of the People’s Republic of Bangladesh continues to provide our teams with incredible support for the testing and preparedness of an accelerated commercialization pathway for Ivectosol 1%,” said Dennis Hancock, CEO of Mountain Valley MD in a statement.
“Our pharmaceutical partners are both FDA and EU compliant and support our broader objectives to scale for global production. Securing top quality manufacturing within a competitive cost structure is critical to align with one of the core tenets of MVMD’s mission to ensure accessibility to our technology for even the most disadvantaged nations.”
Dr Abdullah Al Mahamud, a PhD Fellow at Bangladesh Agricultural University, Mymensingh, will be overseeing the trials.
“Our government and its pharmaceutical partners realize the potential of this transformational project to not only impact our husbandry animal health, but also lay the groundwork to apply immediate effort on key human health applications,” he said.
Mountain Valley MD plans to pursue the broad husbandry and companion animal markets with its Ivectosol 1% technology to open up new applications such as poultry and duck that were not previously possible based on viscosity limitations of the generic Ivermectin drug to treat and prevent parasites in cattle, swine, goats and poultry.
The study is also anticipated to demonstrate superior ease of administration by eliminating typically heavy restraint requirements and injection pain for the animal through needleless application, while dramatically reducing the risk of potentially fatal clostridial infection common with traditional injection site penetration from large gauge needles.
Contact Angela at firstname.lastname@example.org
Follow her on Twitter @AHarmantas